Comparison between efficacy of genicular nerve neurolysis and radio frequency ablation in knee osteoarthritis patient.

Comparative study in between the efficacy of genicular nerve alcohol neurolysis and radiofrequency ablation for pain management in patients with knee osteoarthritis - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087909

Enrollment

Registered

2025-05-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue Health Condition 2: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Alcohol neurolysis: Each genicular nerve will be injected with 75 percent alcohol solution for neurolysis. The procedure will be performed under fluoroscopic guidance using standard ase

Eligibility

Inclusion criteria

Inclusion criteria: Patients with knee osteoarthritis Grade 3 or Grade 4. Patients with symptomatic knee osteoarthritis that is non-responsive to conservative modalities. Patients with a failed knee replacement. Patients who are not good surgical candidates due to medical comorbidities and or high body mass index. Patients who want to avoid surgery. Patients who have had a previously successful genicular nerve radiofrequency ablation, as this procedure can be repeated to address recurrent symptomatic knee osteoarthritis.

Exclusion criteria

Exclusion criteria: Patients with knee pain due to causes other than knee osteoarthritis, such as meniscopathy, trauma, spine disorder, or rheumatoid arthritis. Patients with a history of previous knee surgery. Patients who have received intra-articular injection in the last three months. Patients with coagulopathy. Patients with infection. Patients with severe psychiatric illness. Patients with a cardiac pacemaker. Patients with renal or hepatic insufficiency. Patients on disulfiram therapy.

Design outcomes

Primary

Measure	Time frame
Reduction in knee pain severity as assessed by the Visual Analogue Scale.Timepoint: Baseline, 1 week, 1 month, and 3 months post-procedure	—

Secondary

Measure	Time frame
Improvement in physical function WOMAC score. Patient satisfaction score. Incidence of adverse events. Timepoint: Baseline, 1 month, 3 months	—

Countries

India

Contacts

Public ContactShashi Prakash

Institute of medical sciences Banaras Hindu university

dr.shashi.prakash@gmail.com9453047154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026